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Abstract 
An  8-month  old  girl,  weighing  9  kg,  was
brought  by  her  parents  at  8.15  am  to  the
Emergency Department (ED) for a progressive
worsening of weakness and acute respiratory
failure. On admission, the baby presented with
poor  oral  intake,  a  weak  cry  and  extremely
weak  muscular  body  control.  Poor  gag  and
suck, unreactive mydriasis, hypotonia, lethar-
gy  and  absence  of  peristalsis  were  noted.
Laboratory data showed severe respiratory aci-
dosis.  Chest  X-ray,  electroencephalography,
encephalic CT scan and MRI were all normal,
as were cerebrospinal fluid analysis and viral
tests. Orotracheal intubation and continuous
mechanical  ventilation  were  applied.  The
patient received fluids, corticosteroids, aerosol
therapy, large-spectrum antibiotics and enter-
al-nutrition.  Further  investigation  revealed
ingestion  of  an  improperly  prepared  home-
canned homogenized turkey meal. Type A bot-
ulinum  neurotoxin  was  identified.  Trivalent
botulinum  antitoxin,  prostigmine  and  oral
activated  charcoal  were  administered.
Generalized flaccid paralysis, areflexic bilater-
al mydriasis, gastric stasis and deep coma per-
sisted for the duration of the hospital stay, and
the patient died of severe respiratory failure
and cardiac arrest 12 days after ED admission.
Botulism poisoning should be suspected in any
infant  presenting  with  feeding  difficulties,
constipation,  descendent  paralysis  or  acute
respiratory failure. Supportive treatment and
antidotal therapy should be performed as soon
as a clinical diagnosis is made. We describe a
case of foodborne botulism in an 8-month old
infant  caused  by  ingestion  of  an  improperly
prepared  home-canned  homogenized  turkey
meal,  representing  the  youngest  fatal  case
reported in medical literature.
Introduction
Botulism is a neuroparalytic disease caused
by the blockade of neural transmission in the
cholinergic synapses due to botulinum neuro-
toxins.  These  are  mainly  produced  by  the
Clostridium botulinum or, rarely, by the neuro-
toxigenic  Clostridium  butyricum and
Clostridium baratii. These neurotoxins can be
distinguished  in  seven  types  (A-G).  The
human botulism is primarily related to types A,
B, E and rarely to type F. All forms of botulism
(foodborne,  wound,  infant  botulism,  adult
intestinal toxemia, inhalational and iatrogenic
botulism) are characterized by the same clini-
cal  syndrome,  including  an  acute/subacute
afebrile condition and symmetric descending
flaccid  paralysis.1 Foodborne  botulism  is
caused by ingestion of preformed toxin in food.
The  onset  of  clinical  manifestations  can  be
rapid and dramatic, differing from the infant
form which usually develops less rapidly as the
result of progressive intestinal colonization by
neurotoxigenic  clostridia  and  subsequent
intraluminal  production  and  absorption  of
toxin.2 We describe here a case of foodborne
botulism in an 8-month old infant caused by
ingestion  of  an  improperly  prepared  home-
canned homogenized turkey meal, represent-
ing what is to our knowledge the youngest fatal
case reported in medical literature.
Case Report
An  8-month  old  girl,  weighing  9  kg,  was
brought  by  her  parents  at  8.15  am  to  the
Emergency Department (ED) for a progressive
worsening  of  weakness  and  dyspnea  which
had appeared two hours before. Medical histo-
ry was negative for perinatal or delivery com-
plications, and the baby was normal for devel-
opment and growth; the mother had had no
prenatal  infections.  Physical  examination
revealed a body temperature of 36.6°C, oxygen
saturation of 86% on room air, blood pressure
of 90/40 mmHg, pulse rate of 160 beats/min
and  respiratory  rate  of  44  breaths/min.  The
patient’s  general  appearance  was  lethargic
with  pallor,  poor  oral  intake,  weak  cry  and
weak muscular body control. Pulmonary clini-
cal  evaluation  showed  bronchostenosis,  dif-
fuse wheezing and murmur reduction at the
right  lower  lung  field.  Laboratory  analysis
revealed white blood cell count of 15.9¥109/L
(27%  neutrophils  and  62%  lymphocytes).
Serum  sodium  level  was  128  mEq/L,  serum
magnesium  1.7  mg/dL,  blood  glucose  178
mg/dL and lactate dehydrogenase 602 IU/L. All
other  parameters  were  in  the  normal  range
including hemoglobin (13.50 g/dL), hematocrit
(40.7%), potassium (3.5 mEq/L), chloride (97
mEq/L) and calcium (9.9 mg/dL). Initial arteri-
al blood gases on room air showed a pH value
of  6.89,  oxygen  tension  36.4  mmHg,  carbon
dioxide tension 121 mmHg, bicarbonate 12.5
mmoL/L, lactate 2.2 mmoL/L and base excess of
-9.4 mmoL/L with oxygen saturation of 48.4%.
The patient was promptly intubated and treat-
ed with intravenous fluids (500 mL of 5% dex-
trose solution and 8 ml of 0.9% sodium chlo-
ride at a 30 ml/h infusion rate), hydrocortisone
80 mg intramuscularly, methylprednisolone 8
mg intravenously associated with adrenaline
0.5 mg, and beclometasone 0.8 mg by aerosol.
Chest X-ray, EEG, cranial CT scan and MRI, as
well as cerebrospinal analysis were all normal.
Two hours after arrival in the ED the patient
was  transferred  to  the  Paediatric  Intensive
Care  Unit  (PICU)  of  the  nearest  hospital
where  volume-cycled  mechanical  ventilation
(FiO2 0.5, PaO2/FiO2 ratio 177.2) was started.
At PICU admission, the infant was minimal-
ly  responsive,  with  some  visual  response  to
pain, poor cough and minimal gag. Pulmonary
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clinical evaluation showed expiratory whistles
and diffuse moist rales in both lungs; thick cor-
puscular  secretions  were  aspirated  through
the oro-tracheal tube and collected for cultural
assays. During the first six hours in PICU the
clinical picture worsened to a lethargic and dif-
fusely hypotonic child with unreactive mydria-
sis, poor gag and suck, and absence of peristal-
sis and tendon reflexes.  
Further investigation revealed that, the day
before, the patient had ingested an improperly
prepared  home-canned  homogenized  turkey
meal. Parents revealed that during the canning
procedure,  jars  filled  with  turkey-meat  had
been boiled without a pressure cooker, stored
at room temperature and not re-warmed before
feeding.  Foodborne  botulism  was  suspected.
Serum, food leftover samples (that appeared
greenish and had a bad smell), rectal swabs
and four unopened jars of food were immedi-
ately  sent  to  the  Italian  National  Reference
Centre for Botulism at the National Institute of
Health for laboratory analysis. Botulism poi-
soning  was  confirmed  after  ten  hours.  A
mouse-bioassay testing of food leftovers was
positive for type A toxin with 4000 Minimal
Lethal Dose (MLD) per gram of food. C. botu-
linum type A was also detected by PCR assay
and cultural method in both food leftovers and
rectal  swabs.  On  Day  2,  electromyography
showed low amplitude, short-duration, abun-
dant  motor-unit  action  potentials  consistent
with the described pattern of botulism poison-
ing.3 During  hospitalization,  the  patient
received  symptomatic  treatment  with  fluids,
enteral  nutrition,  methylprednisolone  10  mg
bid,  ranitidine  25  mg/day,  18%  mannitol  10
ml/day,  and  large  spectrum  antibiotics  (cef-
tazidime 250 mg bid for the first two days and
subsequently  ceftriaxone  700  mg/day).
Fluconazole  (400  mg/day)  was  started  from
Day 4, paracetamol (250 mg bid) from Day 5
and albumin (10 mL/day) from Day 6. Trivalent
botulinum  antitoxin  was  obtained  from  the
Health Ministry stockpile and then adminis-
tered intravenously (250 mL, 25 mL/h infusion
rate) 10 h after laboratory confirmation of poi-
soning. Oral activated charcoal (5 g by naso-
gastric  tube)  and  intravenous  prostigmine
(0.05 mg/kg bid) were also administered. Eight
days after admission, an EEG revealed diffuse
subcortical distress that worsened to a flat EEG
during the following 24 h. Generalized flaccid
paralysis, areflexic bilateral mydriasis, gastric
stasis of 20-40 mL/die and deep coma with GCS
3 persisted for the duration of hospital stay,
and the patient died from severe respiratory
failure  and  cardiac  arrest  12  days  after  ED
admission.
Discussion
Botulism  in  infancy  is  rare.  The  ‘infant’
form is reported the most frequently under one
year of age.1,2,4 In one case of foodborne botu-
lism described in the US, the patient (a six
month-old infant) gradually recovered from a
severe neuroparalytic picture after a 6-week
period  of  intensive  care.5 Foodborne  cases
have  also  been  reported  in  1  to  2  year-old
infants (2 fatal and 3 non-fatal cases) mostly
due to ingestion of home-canned baby food.5,6
In Italy, infant botulism has been the only form
diagnosed in infants, with a total of 32 cases
reported from 1984 to July 2011. Our case rep-
resents the first foodborne botulism involving
an infant under the age of one year in Europe
and  the  youngest  fatal  botulism  case  ever
reported.  The  severe  respiratory  failure
observed in this patient was consistent with
ingestion of a large dose of type A toxin, the
most potent type of botulinum neurotoxins.7
Laboratory confirmation was made by the offi-
cial  mouse-bioassay  (intraperitoneal  injec-
tions of white mice unprotected and protected
with polyvalent botulinum antitoxin) and real
time PCR, a valuable technique recently intro-
duced to detect pathogenic micro-organisms in
food,  environmental  and  clinical  samples.1,8
Based on the toxin level found in the food left-
overs and the estimated consumption of about
50 g of contaminated food, the type A neurotox-
in dose ingested by the patient was probably as
high as 200,000 MLDs.
The antidote used in this patient (250 mL
Trivalent  Equine  Antitoxin,  Behring)  can
induce passive immunization due to the neu-
tralization of the circulating toxins. There are
currently three different botulinum antitotoxin
formulations available in Europe and the US
(Table  1).1,9,10,11 The  Trivalent  Equine
Antitoxin is indicated for all forms of botulism.
Notably,  the  recommended  dose  of  the
European  antidote  is  approximately  50-fold
higher compared to the US HBAT.
In fact, the appropriate dosage for the anti-
toxin formulations currently used in botulism
is still a subject of debate. In particular, for the
European  antidote,  there  is  no  information
available in literature, nor any guidance from
the manufacturer on the management of botu-
lism  in  infancy.  Recently,  the  US  FDA  has
licensed  an  intravenous  human-derived
immune-globulin  preparation  (BabyBIG)  for
infant botulism (Table 1).11 There is only one
report describing the use of this product for
treatment of foodborne disease in infancy.5
Our  patient  received  supportive  therapy,
gastrointestinal decontamination and antidot-
ic treatment. Prostigmine was given to con-
trast  the  anticholinergic-induced  ileus  and
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Table 1. Botulinum Antitoxin formulations available in Italy and in the US.
Botulinum  Formulation Antitoxin Concentration per vial/ Concentration  Dosage and route  Clinical  Ref.
antitoxin types bottle (IU) per mL (IU) of administration indication
Trivalent equine  250 mL / bottle anti-A 187500 750 2 bottles i.v. All botulism forms 1
antitoxin®(Behring) anti-B 125000 500
anti-E 12500 50
US HBAT investigational  20 mL / vial anti-A 7500 375 1 vial i.v. All botulism forms 1, 9, 10
heptavalent equine  anti-B 5500 275 except infant botulism
antitoxin,   anti-C 5000 250 type A or B
(Cangene Corporation) anti-D 1000 50
anti-E 8500 425
anti-F 5000 250
anti-G 1000 50
Botulism immune  Single-dose vial  anti-A At least 15 2.0 mL/kg  Infant botulism  11
globulin intravenous containing  anti-B At least 2.0 (100 mg/kg) i.v. type A or B
(Human) (BIG-IV)  100 mg±20 mg 
(Baby BIG®)  of lyophilized 
(Massachusetts public  immunoglobulin
health biologic
laboratories and cangene 
corporation)[page 124] [Pediatric Reports 2011; 3:e31]
facilitate  removal  of  the  contaminated  food,
spores and toxins from the gut.1,12 Based on
the estimated amount of the toxin ingested,
the  administered  dose  of  the  antitoxin  was
likely high enough to neutralize the circulating
poison. Despite precise patient history, prompt
laboratory investigation and treatment, clinical
evolution was progressively rapid and fatal.
Preventing food contamination remains the
most  relevant  approach  for  botulism.  People
using  home  canning  and  food  preservation
processes should be educated about the correct
time, pressure, and temperature required to
destroy spores and botulinum toxins. Clinical
manifestations of botulism in infancy may be
difficult to recognize because of its insidious
onset and the lack of a specific history.13 The
antidotic management of severe poisoning in
infants has still not been clarified. 
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